单细胞追踪揭示黑色素瘤 TIL 治疗过程中肿瘤反应性 T 细胞的可塑性
Single-cell tracking reveals tumor-reactive T cell plasticity during melanoma TIL therapy.
TIL(肿瘤浸润淋巴细胞)过继细胞治疗可在转移性黑色素瘤中诱导持久缓解,然而在体外扩增过程中及回输后,调控肿瘤反应性T细胞命运的克隆和转录动态仍知之甚少。
英文原题:Local Single-Dose Radiation Improves Adoptive Cell Therapy With Tumor-Infiltrating Lymphocytes.
Local Single-Dose Radiation Improves Adoptive Cell Therapy With Tumor-Infiltrating Lymphocytes.
在肿瘤切除前进行RT以增强TIL扩增,以及在ACT当天进行RT以促进T细胞浸润,这两个不同时间点的RT显著提高了ACT的疗效。这些发现凸显了将RT与ACT联合使用以改善转移性疾病治疗效果的潜力。
放射治疗(RT)增强肿瘤反应性T细胞过继细胞治疗(ACT)的潜力尚未得到充分探索。本研究评估了RT与ACT的联合应用,在两个关键时间点施加RT:(1)肿瘤切除前,以改善TIL(肿瘤浸润淋巴细胞)的体外扩增;(2)在ACT当天使用抗原特异性T细胞,以增强转移后的T细胞浸润。
使用鼠源HPV阳性头颈部鳞状细胞癌(HNSCC)模型,我们在肿瘤切除前5天给予单次剂量RT(8 Gy 1)。进行RNA测序以检测RT后趋化因子的表达。将肿瘤碎片在白细胞介素-2(IL-2)中培养以扩增TIL,并通过细胞因子产生试验评估TIL反应性。对荷瘤小鼠使用来自未治疗或RT治疗肿瘤扩增的TIL进行ACT治疗。在额外实验中,我们评估了RT联合ACT是否能改善T细胞浸润和抗肿瘤活性。
RT预处理显著增强了离体TIL扩增(96% vs 74%;P < .05),并增加了肿瘤坏死因子(TNF-)的产生(P = .03),表明反应性改善。RT还显著增加了TNF- + GzmB + CD8 + TIL的扩增(P = .02),表明细胞毒性亚群内的多功能性增强。RNA测序显示趋化因子(如CCL21和CXCL10)及其受体(CCR7和CXCR4)上调,支持TIL募集增强。使用来自RT预处理肿瘤的TIL进行ACT显示出优越的肿瘤控制,50%的小鼠实现完全肿瘤消退(CR),而对照组为12.5%。与仅接受ACT或RT的小鼠相比,在ACT当天进行RT增加了T细胞向肿瘤的浸润并改善了肿瘤排斥。
INTRODUCTION: The potential for radiation therapy (RT) to enhance adoptive cell therapy (ACT) with tumor-reactive T cells has not been fully explored. This study evaluated combining RT with ACT, applying RT at two critical time points: (1) before tumor resection to improve ex vivo expansion of tumor-infiltrating lymphocytes (TIL) and (2) on the day of ACT using antigen-specific T cells to enhance T cell infiltration after transfer. METHODS AND MATERIALS: Using a murine human papillomavirus (HPV)-positive head and neck squamous cell carcinoma (HNSCC) model, we administered single-dose RT (8 Gy 1) 5 days before tumor resection. RNA sequencing was performed to measure chemokine expression post-RT. Tumor fragments were cultured in interleukin-2 (IL-2) for TIL expansion, and TIL reactivity was assessed through cytokine production assays. Tumor-bearing mice were treated with ACT with TIL expanded from untreated or RT-treated tumors. In additional experiments, we assessed whether RT given in combination with ACT could improve infiltration of T cells and antitumor activity. RESULTS: RT preconditioning significantly enhanced ex vivo TIL expansion (96% vs 74%; P < .05) and increased tumor necrosis factor (TNF- ) production (P = .03), indicating improved reactivity. RT also significantly increased the expansion of TNF- + GzmB + CD8 + TILs (P = .02), suggesting enhanced polyfunctionality within a cytotoxic subset. RNA sequencing revealed upregulation of chemokines (eg, CCL21 and CXCL10) and their receptors (CCR7 and CXCR4), supporting enhanced TIL recruitment. ACT with TIL from RT-preconditioned tumors demonstrated superior tumor control, with 50% of mice achieving complete tumor regression (CR) compared with 12.5% in controls. RT on the day of ACT increased T cell infiltration into tumor and improved tumor rejection compared with mice receiving either ACT or RT alone. CONCLUSIONS: RT at two distinct time points-before tumor resection to enhance TIL expansion and on the day of ACT to boost T cell infiltration-significantly improves the efficacy of ACT. These findings highlight the potential for combining RT with ACT to enhance therapeutic outcomes in metastatic disease.
MEMBER ACCOUNT
登录成功会直接打开下一页。